Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PISTIAS-3): a Randomized, Double-blind, Placebo-controlled Trial

NCT07466251 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT07466251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07466251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PISTIAS-3): a Randomized, Double-blind, Placebo-controlled Trial
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 31, 2029
Enrollment
1,212 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke ais, atherosclerotic plaque, intracranial atherosclerosis icas